If you have read our honest take on the research gap in cannabis, this is the animal version of the same argument.
What is actually established
Mammals have an endocannabinoid system. This is not in dispute. It is a signalling network involved in a range of ordinary body functions, and it is present in dogs, cats, rabbits, horses and every other mammal on this site.
That is the foundation, and it is genuine. It is also the point at which a lot of marketing stops, because the next step is where it gets harder.
Having a receptor system is not evidence of an outcome. A mechanism that could plausibly do something is not the same as demonstrated evidence that it does. Most pet CBD marketing moves from the first to the second in a single sentence, and that sentence is where the overreach happens.
Where the evidence is strongest
Dogs, and joint comfort and mobility in particular.
Dogs are the best-studied companion species for CBD by a clear margin, and within that, work on mobility and joint comfort in older dogs is where the published research is most concentrated. This is also where owner reports are most consistent, which matters: when a controlled signal and a large body of owner observation point the same way, that is more persuasive than either alone.
What “strongest” means here. It means a developing evidence base with some encouraging findings, not a settled question. Results have not been uniform. Sample sizes in animal work are often small. Some of the research has industry involvement, which is not disqualifying but is worth knowing.
If someone tells you the dog joint evidence is conclusive, they are overstating it. If someone tells you there is nothing there, they are also wrong.
Where the evidence is thin
Behaviour and anxiety. Owner reports are numerous and enthusiastic. Controlled evidence is considerably thinner, and results have not been consistently positive.
There is a specific reason to be cautious here rather than merely uncertain. Behaviour is the area where the passage of time, changes in routine, and an owner’s hopes are hardest to separate from the thing being tested. People who start a supplement usually change other things at the same time, and a dog whose owner is paying more attention to it is a dog whose behaviour changes for reasons unrelated to any bottle.
Cats generally. There is work on how cats absorb and process cannabinoids, which is genuinely useful because it establishes that cats are not small dogs in this respect. What is much scarcer is controlled work showing a specific outcome in cats for a specific problem.
Where the evidence does not exist
Rabbits, guinea pigs, chinchillas and small rodents. Very little. This is why every small-mammal page on this site routes to an exotics vet, and why those pages talk about the measurement problem before anything else. That is not editorial caution. It is the accurate description of the situation.
Horses. Interest is high and published work is limited. There is also a regulatory dimension that has nothing to do with efficacy: competition governing bodies prohibit cannabinoids, which constrains research and use alike.
Any claim that CBD treats, prevents or cures a diagnosed condition in an animal. There is no evidence base for this in any species, and a company making that claim is making a regulatory problem as well as a factual error.
Why the marketing runs ahead of the evidence
Worth naming, because it explains what you are reading everywhere else.
The mechanism is real, which makes the leap feel small. “Animals have an endocannabinoid system” is true, and it is one short step from there to an implied benefit. The step is short and it is not justified.
Owner reports are abundant and they feel like data. Thousands of people describing the same thing is not nothing. It is also not a controlled trial, and it cannot rule out the explanations that a controlled trial exists to rule out.
Nobody is rewarded for saying “we do not know.” A brand that publishes the uncertainty loses to a brand that publishes a benefits list, at least on the first visit.
We would rather lose that first visit.
Practical takeaways
Treat it as something worth trying, not something known to work. That framing sets the right expectation and it is also the accurate one.
Run it like a small experiment. Write down a baseline of three or four specific, countable things before you start. Change one variable at a time. Give it a fair run of days. Then judge honestly, including being willing to conclude it did nothing.
Do not use it in place of veterinary care. This is the practical harm that follows from overstated marketing: an animal with a treatable condition that goes undiagnosed for months while an owner works through supplements. That harm is real and it does not require the supplement to have any side effects at all.
Insist on the things that are not uncertain. THC-free with a certificate, contaminant screening, a stated CBD amount, a product made for the species. None of that depends on the efficacy question, and all of it is verifiable. → How to read a lab report
Read next How to read a lab reportWhy we are telling you this
Because the alternative is worse for us.
A customer who buys on an overstated promise, sees nothing, and concludes the whole category is a scam is a customer we have lost permanently and deserved to lose. A customer who buys knowing the evidence is developing, tries it properly, and gets an honest answer either way is one who trusts what we say next.
The honest version is also the only version we can defend when somebody asks us to show our working.
The short version
- Mammals have an endocannabinoid system. That is established, and it is not the same as demonstrated benefit.
- Dogs and joint mobility is the strongest area, and it is developing rather than settled.
- Behaviour and anxiety evidence is thinner than the marketing suggests.
- For cats the picture is limited. For small mammals and horses it is thinner again.
- No evidence supports treating any diagnosed condition in any species.
- Run it as an experiment with a written baseline, and never in place of veterinary care.